Translational study showing ruxolitinib and JAK2 suppression select for RAS pathway–mutant clones in myelofibrosis, enhancing their fitness via MAPK activation and linking this selection to worse clinical outcomes in treated patients.
0:00Welcome to Base by Base, the papercast that brings genomics to you wherever you are. Thanks for listening, and don't forget to follow and rate us in your podcast app. So uh, what really happens when a highly effective targeted cancer drug inadvertently acts like a biological sieve.
0:16Like selecting for a far deadlier version of the disease you mean. Exactly. Imagine reading a garden by removing all the, you know, the dominant plants only to realize you've just created the perfect sunlit real estate for a much more aggressive, deeply rooted weed to take over.
0:30How could this change the way we treat blood cancers? Well, today, we celebrate the work of a massive collaborative team, and this includes Nubi Masla, Nina Kochi, Blending and Ru, Lina Benajiba, and researchers from University of Paracite, Insurm, and Dana Farber Cancer Institute.
0:46Wow, there is a huge group. It really is. And they've significantly advanced our understanding of myoproliferative neoplasms. This deep dive is actually based on their open access article titled JAK2 inhibition mediates clonal selection of RAS pathway mutations in myla proliferative neoplasms.
1:02Which was published in nature communications on July 08, 2025, right? Yes, exactly. Okay, let's unpack this. For anyone working with or studying myoproliferative neoplasms or MPNs, the underlying biology is pretty familiar.
1:17We are looking at a state of constitutive activation within the Jackstat signaling pathway. Right, which is usually driven by those classic driver mutations, you know, in JK2, CLR MPL. Yeah. And the standard of care shifted dramatically, like, about a decade ago, with the introduction of Targeted JK inhibitors, right?
1:33Right. With Ruxalitendib being the massive 1st in-class breakthrough. It was huge. The clinical utility of Rexelet Nib has been undeniably robust. I mean, it's successfully dampens that overactive jade pathway.
1:46Which directly translates to shrinking those massive spleens, right? Exactly. Massive spleen size reductions, and it significantly alleviates the severe symptoms that just, well, degrade a patient's quality of life.
1:56From a pharmacological standpoint, the drug does exactly what it was engineered to do. There's a catch. Yeah, there is. If we connect this to the bigger picture, the complication arises when we map that success onto the biological reality of intrapatient tumor heterogeneity.
2:11Right, because cancer isn't just one monolithic thing, you're dealing with this dynamic ecosystem where genetically diverse subclones are basically competing for resources in the bone marrow. Spot on. So the clinical question becomes, does the selective pressure of a drug like ruxillaton nib, suppress the dominant clone only to, you know, clear the runway for a more aggressive subclone to expand?
2:36That's such a tough position for doctors. I mean, put yourself in the shoes of a clinician. You have a therapy that gives immediate, tangible relief to your patient right now. But you have to weigh that against how the disease might evolve over a span of years.
2:47Exactly. So how do the researchers actually test this? Well, they knew that to definitively answer, if Ruxolitanib drives this aggressive clonal selection, they needed long-term, real-world data. So they established a cohort of 143 patients diagnosed with milo fibrosis.
3:04Which is a really rigorous sample size for this specific condition, honestly. It is. They used a natural comparison point. They tracked 72 patients actively treated with Rexalitanib against a control group of 71 patients who didn't receive the drug.
3:18To monitor the evolutionary shifts over time, they deployed a longitudinal next generation sequencing panel, right, covering, I think, 36 specific myeloid genes. Yeah, 36 genes. And when you look at bulk sequencing over time, you can clearly see the allele frequencies of certain mutations going up or down between the baseline and follow-ups years later.
3:39But wait, let me push back here for a second. How do they know these mutations weren't just a natural progression of the disease? I mean, mylofibrosis naturally has genomic instability. If a patient is on the drug and a mutation expands, bulk data alone doesn't prove the drug caused it.
3:54Right. That is the exact hurdle they had to overcome. To isolate causation from correlation, they had to move way beyond just bulk sequencing. So what do they do? They utilize single cell DNA sequencing on primary CD 34 positive human cells.
4:08These were collected directly from the patients and treated ex vivo. Oh, wow. So at single cell resolution, you're not just looking at a soup of mutations. You can literally reconstruct the phylogenetic tree of the cancer.
4:20Exactly. You can see if a rising RAS mutation exists totally on its own, or if it explicitly co-occurred inside the exact same blast cell as the original JAK2 mutation. So by tracking that exact cellular lineage, they can see if a specific subclone, the one with both mutations, suddenly gets a survival advantage the moment you expose it to the JK inhibitor.
4:42Right. And they saw that advantage directly, but they didn't stop there. To prove it happens in a living system, they constructed highly controlled invivo competitive bone marrow transplants. Min mice, right.
4:53Yes, they irradiated the mice to clear out their existing bone marrow, creating a blank slate. Then they engrafted them with a calibrated mix of stem cells. Okay, so what was the mix? One population had a mutated JAK2 gene, but a wild type RAS gene.
5:07The competing population had a wild type JAK2, but a mutated RAS gene. Ah I see. So by putting these 2 profiles into direct competition in the same mouse, you're basically recreating the heterogeneous bone marrow of a human patient.
5:20Exactly. Then you introduce the Rexalitnib therapy and just watch the engraftment ratios over several weeks to see who wins the space. And who won? The selective pressure from the drug systematically favored the RAS mutated cells.
5:34The Invivo mouse models perfectly mirrored the single cell data. It proved the drug itself was the catalyst for the expansion. Not just a bystander. Wow. Okay, well, here's where it gets really interesting.
5:45When you look at how this biological mechanism translates back to the bulk clinical data of those 143 human patients. The statistical signal is just massive. Staggering, honestly. Right, in the cohort treated with Ruxolitneb, the accumulation of new mutations in the RES signaling pathways, specifically in genes like NRAS, KRAS, and CBL, happened at a drastically accelerated rate.
6:07We're talking about a hazard ratio of 9.8 compared to untreated patients. And a hazard ratio of almost 10 indicates a fiercely powerful selective advantage. But the really grim part is how this redirects the disease trajectory.
6:21Yeah, the transformation rate. Right. In the treated patients who developed these RAS mutations, 47% underwent leukemic transformation. They progressed into secondary acute myloid leukemia or myelodysplastic syndromes.
6:3447%. That is nearly half That fundamentally changes the risk benefit calculus for managing long-term care. Yeah, especially when you compare to the untreated patients with RES mutations. Yeah, in that untreated group, only 16.7% experience that severe leukemic transformation.
6:51And the overall survival data is equally stark, isn't it? Very. For treated patients without RES mutations, the median overall survival was 18.5 years. But if RAS mutation emerged under treatment. Let me guess, it dropped.
7:04It plummeted. The median survival dropped to just 7.6 years. Wow. Okay, so the clinical data establishes a clear causal link between the therapy and a severe reduction in lifespan due to this clonal evolution, but this presents a huge paradox.
7:18Well, how does a therapy engineered to arrest cellular proliferation, end up creating an environment where a specific, highly mutated cell population just multiplies aggressively. I mean, if a cell has a mutation driving growth, inhibiting that pathway should stop it.
7:36It should theoretically neutralize it. yes The fact that it does the exact opposite points to a really fascinating secondary mechanism. It's basically a biological Goldilocks principle. Okay, I love a good analogy.
7:47Break that down for it. So it hinges on the relationship between the Jackstat pathway and the MPK pathway. Now, RAS mutations constituently activate the MPK pathway. Right. switched on. Exactly. And in these MPN patients, the primary driver mutation is already keeping the jack pathway permanently on too.
8:04So if a single cell acquires a secondary RAS mutation, it's suddenly getting maximum growth signals from both pathways at the same time. And that combined signal is just too much, right? The mitogenic input would overload the cell's regulatory framework.
8:17It totally overloads it. The cell gets an overwhelming mandate to replicate, which causes severe DNA replication stress. So the cell initiates a failsafe. On cajine induced senescence. Bingo. The excessive signaling activates cell cycle arrest proteins.
8:33It basically forces the cell into a permanent biological dormancy. So it doesn't die. It just, you can't divide. Right. The cell's engine is running so high that it shuts itself down to prevent damage.
8:44The RES mutation actually neutralizes its own ability to expand because the signal is too high. So this super aggressive RAS clone is just sitting there, trapped as a tiny, dormant faction of the tumor burden, until the patient starts ruxle it and nib.
8:59Exactly. The drug successfully inhibits the JK pathway. So the overall volume of growth signaling inside that darm cell drops. It drops out of the overload zone and lands in the Goldilocks. So Yes. The signal isn't intense enough anymore to maintain the oncogene induced senescence.
9:14The biological brakes come off. And because it still has the RAS mutation driving the MAPK pathway, it wakes up and resumes dividing. And now it has a massive competitive advantage because the dominant JK driven cells all around it are being suppressed by the drug.
9:29Oh my god. The targeted therapy acts as the exact physiological switch that releases the subclone from its own arrest. You're clearing out the cellular canopy and giving the dangerous weed the sunlight to take over.
9:43It's a perfect illustration of the feedback leaps in cancer networks. Targeted therapies aren't just isolated interventions. They apply pressure across the whole ecosystem. So what does this all mean? Clinically speaking, I mean, if the very mechanism that makes the inhibitor work is what wakes up the RES clones, that completely changes how we should prescribe it.
10:02This raises an important question, right? It absolutely demands advanced molecular screening before initiating targeted therapy. Right now, a diagnosis in a JAK 2 mutation is usually enough to prescribe ruxolicitive or federative or mammolitinib.
10:17But this research says doctors need to use sensitive sequencing to hunt for those dormant RAS mutations first. Before writing the prescription, yeah. If they find a dormant RES clone, even at a tiny fraction, they know the drug will likely wake it up.
10:29But you can't just withhold a great drug from a sick patient either. So what's the move? Well, the researchers anticipated that dilemma. Because they understood the escape route, the MEPK pathway, they mapped out a combinatorial approach.
10:43Adding another drug to the mix. Right. In their lab models, they added a MEK 12 inhibitor, specifically Trematonib. MEK is a downstream effector in that Razmat PK cascade. So dual suppression. You hit Jake to alleviate the main disease burden, which accidentally tries to wake up the RAS clones.
11:02But the MEK inhibitor is already there, blocking the MPK pathway those clones need to grow. In the models, this totally prevented the mutant clones from expanding. It's like putting out a fire by removing the fuel, but also cutting off the oxygen, so no secondary fires can start.
11:16This is a huge rationale for new clinical trials. It is, but we also have to remember the limitations here. We shouldn't throw the baby out with the bathwater. Ruxalitinib remains highly beneficial for many patients.
11:27Right, what were the numbers again? Only about 24% of the treated patients harbored these emergent RAS clones compared to 8% in the untreated group. Okay, so for like 3 quarters of the patients. The drug works exactly as intended without waking up this specific threat.
11:42We just need to be far more precise with molecular screening. Exactly. We have to manage the longitudinal evolution of the genetic landscape. Not just treat the immediate symptoms. Wow. Okay, so to wrap this up, targeted therapies like Ruxolitinib, apply selective pressure that can inadvertently awake dormant, aggressive RES mutated clones by releasing them from oncogene induced senescence.
12:05To safely treat myoproliferative neoplasms moving forward, clinicians really must monitor this dynamic clonal evolution and consider combinatorial treatments. That sums it up perfectly. So, leaving you with a thought.
12:18What does this mean for our broader reliance on single target therapies across other heterogeneous cancers, like skin or pancreatic tumors, where phenotypically silent RES mutations might just be waiting for the right drug to wake them up.
12:30This episode was based on an open access article under the CCBY 4.0 license. You can find a direct link to the paper and the license in our episode description. If you enjoyed this, follow or subscribe in your podcast app and leave a 5 star rating.
12:45If you'd like to support our work, use the donation link in the description. Now stay with us for an original track, created especially for this episode, and inspired by the article you've just heard about.
12:54Thanks for listening and join us next time as we explore more science based by base.
